EP3143123A4 - Induction de régénération cardiaque par micro-arn - Google Patents

Induction de régénération cardiaque par micro-arn Download PDF

Info

Publication number
EP3143123A4
EP3143123A4 EP15792355.8A EP15792355A EP3143123A4 EP 3143123 A4 EP3143123 A4 EP 3143123A4 EP 15792355 A EP15792355 A EP 15792355A EP 3143123 A4 EP3143123 A4 EP 3143123A4
Authority
EP
European Patent Office
Prior art keywords
microrna
induction
cardiac regeneration
cardiac
regeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15792355.8A
Other languages
German (de)
English (en)
Other versions
EP3143123B1 (fr
EP3143123A1 (fr
Inventor
Edward E. Morrisey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to PL15792355T priority Critical patent/PL3143123T3/pl
Publication of EP3143123A1 publication Critical patent/EP3143123A1/fr
Publication of EP3143123A4 publication Critical patent/EP3143123A4/fr
Application granted granted Critical
Publication of EP3143123B1 publication Critical patent/EP3143123B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP15792355.8A 2014-05-16 2015-05-15 Induction de régénération cardiaque par micro-arn Active EP3143123B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL15792355T PL3143123T3 (pl) 2014-05-16 2015-05-15 Indukcja regeneracji serca za pomocą mikroRNA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461994250P 2014-05-16 2014-05-16
PCT/US2015/030990 WO2015175889A1 (fr) 2014-05-16 2015-05-15 Induction de régénération cardiaque par micro-arn

Publications (3)

Publication Number Publication Date
EP3143123A1 EP3143123A1 (fr) 2017-03-22
EP3143123A4 true EP3143123A4 (fr) 2017-10-11
EP3143123B1 EP3143123B1 (fr) 2019-11-27

Family

ID=54480744

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15792355.8A Active EP3143123B1 (fr) 2014-05-16 2015-05-15 Induction de régénération cardiaque par micro-arn

Country Status (9)

Country Link
US (1) US10590419B2 (fr)
EP (1) EP3143123B1 (fr)
CY (1) CY1123144T1 (fr)
DK (1) DK3143123T3 (fr)
ES (1) ES2769030T3 (fr)
MA (1) MA39990A (fr)
PL (1) PL3143123T3 (fr)
PT (1) PT3143123T (fr)
WO (1) WO2015175889A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200108013A1 (en) * 2017-03-31 2020-04-09 The Trustees Of The University Of Pennsylvania Compositions and methods for cardiac regeneration
KR20200096610A (ko) * 2017-12-08 2020-08-12 유니버시티 오브 워싱톤 카르디올리핀 리모델링 및 심근세포 성숙을 검출 및 촉진하기 위한 방법 및 조성물 및 미토콘드리아 기능장애를 치료하는 관련 방법
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20220251552A1 (en) * 2019-03-25 2022-08-11 The Trustees Of The University Of Pennsylvania Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae
EP3936616A1 (fr) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin Thérapie ciblée par micro-arn pour réparation cardiaque
CN112891619B (zh) * 2021-01-28 2021-10-26 四川大学 具有选择性抑制平滑肌细胞表型转化的基因洗脱涂层材料及其制备方法
JPWO2022202930A1 (fr) * 2021-03-23 2022-09-29

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006577A2 (fr) * 2010-07-08 2012-01-12 Duke University Reprogrammation directe de cellules en un devenir de cardiomyocytes
WO2013093870A1 (fr) * 2011-12-23 2013-06-27 International Centre For Genetic Engineering And Biotechnology - Icgeb Microarn pour la régénération cardiaque par l'intermédiaire d'induction de la prolifération de cardiomyocytes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6756196B2 (en) 1999-06-28 2004-06-29 Millennium Pharmaceuticals, Inc. Molecules of the card-related protein family and uses thereof
DE602005017362D1 (de) 2004-02-06 2009-12-10 Dharmacon Inc Stabilisierte rnas als transfektionskontrollen und silencing-reagentien
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
CN101970664B (zh) 2008-01-16 2013-08-21 林希龙 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞
US20100062534A1 (en) 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
US9115345B2 (en) * 2010-04-19 2015-08-25 The Trustees Of The University Of Pennsylvania MicroRNA induction of pluripotential stem cells and uses thereof
EP2790736B1 (fr) * 2011-12-12 2018-01-31 Oncoimmunin, Inc. Administration in vivo d'oligonucléotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006577A2 (fr) * 2010-07-08 2012-01-12 Duke University Reprogrammation directe de cellules en un devenir de cardiomyocytes
WO2013093870A1 (fr) * 2011-12-23 2013-06-27 International Centre For Genetic Engineering And Biotechnology - Icgeb Microarn pour la régénération cardiaque par l'intermédiaire d'induction de la prolifération de cardiomyocytes

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANA EULALIO ET AL: "Functional screening identifies miRNAs inducing cardiac regeneration", NATURE, vol. 492, no. 7429, 5 December 2012 (2012-12-05), pages 376 - 381, XP055342709, ISSN: 0028-0836, DOI: 10.1038/nature11739 *
BARROSO DEL-JESUS A ET AL: "Embryonic Stem Cell-Specific miR302-367 Cluster: Human Gene Structure and Functional Characterization of Its Core Promoter", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 28, no. 21, 1 November 2008 (2008-11-01), pages 6609 - 6619, XP003024778, ISSN: 0270-7306, [retrieved on 20080825], DOI: 10.1128/MCB.00398-08 *
DATABASE Geneseq [online] 15 August 2013 (2013-08-15), "Human microRNA hsa-miR-302a, SEQ ID 16.", retrieved from EBI accession no. GSN:BAP99597 Database accession no. BAP99597 *
DATABASE Geneseq [online] 15 August 2013 (2013-08-15), "Human microRNA hsa-miR-302b, SEQ ID 17.", retrieved from EBI accession no. GSN:BAP99598 Database accession no. BAP99598 *
DATABASE Geneseq [online] 15 August 2013 (2013-08-15), "Human microRNA hsa-miR-302c*, SEQ ID 19.", retrieved from EBI accession no. GSN:BAP99600 Database accession no. BAP99600 *
DATABASE Geneseq [online] 15 August 2013 (2013-08-15), "Human microRNA hsa-miR-302c, SEQ ID 18.", retrieved from EBI accession no. GSN:BAP99599 Database accession no. BAP99599 *
DATABASE Geneseq [online] 15 August 2013 (2013-08-15), "Human microRNA hsa-miR-302d, SEQ ID 20.", retrieved from EBI accession no. GSN:BAP99601 Database accession no. BAP99601 *
J. CHEN ET AL: "mir-17-92 Cluster Is Required for and Sufficient to Induce Cardiomyocyte Proliferation in Postnatal and Adult Hearts", CIRCULATION RESEARCH., vol. 112, no. 12, 10 April 2013 (2013-04-10), US, pages 1557 - 1566, XP055402614, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.112.300658 *
Y. TIAN ET AL: "A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 279, 18 March 2015 (2015-03-18), pages 279ra38 - 279ra38, XP055402607, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.3010841 *

Also Published As

Publication number Publication date
DK3143123T3 (da) 2020-02-10
US10590419B2 (en) 2020-03-17
EP3143123B1 (fr) 2019-11-27
EP3143123A1 (fr) 2017-03-22
PL3143123T3 (pl) 2020-07-13
ES2769030T3 (es) 2020-06-24
US20170096671A1 (en) 2017-04-06
MA39990A (fr) 2015-11-19
PT3143123T (pt) 2020-02-04
WO2015175889A1 (fr) 2015-11-19
CY1123144T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
EP3188790A4 (fr) Stimulation cardiaque
GB201701673D0 (en) Methods of well treatment
EP3140722A4 (fr) Caractérisation d'états de sujet
EP3115076A4 (fr) Cathéter
EP3134436A4 (fr) Traitement de tumeurs provoquées par h-ras
IL248856B (en) New treatment
EP3143123A4 (fr) Induction de régénération cardiaque par micro-arn
EP3120890A4 (fr) Cathéter
IL242971B (en) Reducing the far field in the chambers of the heart
EP3215148A4 (fr) Méthodes pour le traitement d'un déclin cognitif
GB201416832D0 (en) Methods of treatment
EP3236963A4 (fr) Procédé de traitement
EP3096752A4 (fr) Traitement d'une néoplasie
EP3103403A4 (fr) Cathéter
EP3113807A4 (fr) Ballonnet ventriculaire
EP3110455A4 (fr) Traitement des lésions résistantes
GB201418043D0 (en) MicroRNA signatures for cardiac disorders
EP3091985A4 (fr) Traitement de migraines
GB201412010D0 (en) Treatment of hypertransaminasemia
EP3193842A4 (fr) Procédés de préparation d'extrudats
AU2015905220A0 (en) Methods of treatment
AU2014905194A0 (en) Method of Treatment
AU2014904907A0 (en) Method of Treatment
AU2014904371A0 (en) Method of treatment
EP3116996A4 (fr) Traitement de lésions résistantes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20170908

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/077 20100101ALI20170904BHEP

Ipc: C12N 5/00 20060101AFI20170904BHEP

Ipc: C12N 5/02 20060101ALI20170904BHEP

Ipc: A61K 48/00 20060101ALI20170904BHEP

Ipc: A01K 67/027 20060101ALI20170904BHEP

Ipc: C12N 5/0775 20100101ALI20170904BHEP

Ipc: C12N 15/00 20060101ALI20170904BHEP

Ipc: A61K 31/7105 20060101ALI20170904BHEP

Ipc: C12N 15/86 20060101ALI20170904BHEP

Ipc: A61K 31/19 20060101ALI20170904BHEP

Ipc: C12N 15/113 20100101ALI20170904BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180719

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190628

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1206684

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015042597

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3143123

Country of ref document: PT

Date of ref document: 20200204

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20200128

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200207

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20191127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200227

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200400540

Country of ref document: GR

Effective date: 20200511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2769030

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20200430

Year of fee payment: 6

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015042597

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1206684

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191127

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230309

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230310

Year of fee payment: 9

Ref country code: PL

Payment date: 20230314

Year of fee payment: 9

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230516

Year of fee payment: 9

Ref country code: NO

Payment date: 20230510

Year of fee payment: 9

Ref country code: IT

Payment date: 20230412

Year of fee payment: 9

Ref country code: ES

Payment date: 20230602

Year of fee payment: 9

Ref country code: DK

Payment date: 20230511

Year of fee payment: 9

Ref country code: DE

Payment date: 20230321

Year of fee payment: 9

Ref country code: CH

Payment date: 20230602

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20230412

Year of fee payment: 9

Ref country code: GR

Payment date: 20230419

Year of fee payment: 9

Ref country code: AT

Payment date: 20230425

Year of fee payment: 9

Ref country code: FI

Payment date: 20230513

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230418

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20230515

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240312

Year of fee payment: 10

Ref country code: NL

Payment date: 20240315

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240321

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240426

Year of fee payment: 10